PARAXETINE HCL

Paroxetine HCl is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels, used to treat depression, anxiety disorders, OCD, and PTSD. Benefits include mood stabilization and reduction of anxiety and intrusive thoughts. Side effects include nausea, sexual dysfunction, weight changes, insomnia or somnolence, sweating, and discontinuation syndrome if stopped abruptly, as well as rare hyponatremia or serotonin syndrome.

SKU: c0baf24f8e27 Category: Tag:

Product Description


Mechanism of Action

PARAXETINE HCL (ID 27021) exhibits a multidimensional biochemical activity profile involving modulation of enzyme-catalyzed pathways, receptor-mediated intracellular signaling, ion-channel regulation, mitochondrial bioenergetics, oxidative-stress balancing, membrane dynamics, and transcription-factor orchestration. Its molecular configuration allows high-affinity interaction with catalytic residues, allosteric domains, regulatory scaffolds, and signaling intermediates, influencing phosphorylation cycles, second‑messenger flux (Ca²⁺, cAMP, IP₃, DAG), ROS equilibrium, ATP synthesis, and mitochondrial respiratory-chain regulation.

Depending on dose, exposure duration, and cell type, PARAXETINE HCL can modify chromatin accessibility, metabolic flux routing, vesicular trafficking, cytoskeletal structure, and gene-expression clusters associated with survival, inflammation, apoptosis, autophagy, and metabolic adaptation.

Benefits and Advantages

Due to its consistent mechanistic behavior, this compound is utilized in advanced research, including:

  • Receptor–ligand interaction studies and affinity modeling
  • High‑resolution enzyme kinetics and catalytic-pathway deconstruction
  • Mitochondrial ATP‑flux assays and oxidative‑stress system modeling
  • Multi‑omics profiling (transcriptomics, proteomics, metabolomics, phosphoproteomics)
  • Cytoskeletal and membrane‑dynamics exploration
  • Apoptosis, ferroptosis, necroptosis, and autophagy pathway analysis
  • Structure–activity relationship (SAR) investigations and compound optimization
  • Pharmacodynamic modeling, mechanistic dose–response scaling, and pathway benchmarking

Side Effects and Risks

Potential laboratory risks include:

  • Oxidative‑stress imbalance and ROS accumulation
  • Mitochondrial overload or respiratory-chain suppression
  • Ion‑channel dysregulation affecting Ca²⁺/Na⁺/K⁺ homeostasis
  • Unintended receptor cross‑activation or pathway inhibition
  • Cytoskeletal destabilization and membrane‑integrity disruption
  • Dose-dependent cytotoxicity (apoptotic or autophagic induction)
  • Transcriptional or epigenetic instability under prolonged exposure
  • Activation of inflammatory signaling networks (NF‑κB, JNK, p38 MAPK)

Use strictly in controlled laboratory environments with appropriate biosafety protocols.

Datasheet


Molecular Formula

C19H20FNO3·HCl

Molecular Weight

365.24 g/mol

CAS Number

61869-08-7

Storage Condition

Store at 2-8°C

Solubility

Soluble in water

Purity

Purity information is available upon request (COA).

Synonym

3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; 3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; 72473-26-8; 3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; Paxetil

IUPAC/Chemical Name

(3S,4R)-3-(dimethylamino)-1-phenylpropan-1-ol hydrochloride

InChl Key

Unavailable

InChl Code

Unavailable

References

PubChem; ChemBL; FDA;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download